Get started
Author

Emma J Searle

Observed names: Dr. Emma Searle, E. Searle, E.J. Searle, Emma J. Searle, Emma Searle, Searle, Emma
Observed institutions: Manchester Academic Health Science Centre, University of Manchester, The Christie Hospital, The Christie NHS Foundation Trust, Royal Manchester Children's Hospital, Cancer Research UK Manchester Centre
ORCID: 0000-0002-3942-3081
Observed ORCID: 0000-0002-3942-3081
OpenAlex ID: A5032366727
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
2023 · Alexander M. Lesokhin, Michael H. Tomasson, et al. · Nature Medicine · 652
PDF
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
2023 · Luciano Nicosia, Gary J. Spencer, et al. · Cancer Cell · 122
Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
2022 · Emma Searle, Hang Quach, et al. · Blood · 61
Targeting hypoxia in solid and haematological malignancies
2022 · Bill Harris, Sana Saleem, et al. · Journal of Experimental & Clinical Cancer Research · 53
PDF
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations
2023 · Elias Jabbour, Emma Searle, et al. · Blood · 51
Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study
2023 · Jeffrey Matous, Noa Biran, et al. · Blood · 45
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
2024 · Emma Searle, Christian Recher, et al. · Blood · 40
The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy
2021 · Laura Mosteo, Joanna Storer, et al. · Frontiers in Cell and Developmental Biology · 36
PDF
Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
2023 · Emma Searle, Francesco Forconi, et al. · Blood · 34
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
2024 · Nirav N. Shah, Zulfa Omer, et al. · Blood · 33
Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies
2024 · Anita D'Souza, Luciano J. Costa, et al. · Blood · 28
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2024 · Christian Recher, Jenny O'Nions, et al. · Blood · 27
PDF
Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage
2008 · E. Searle, S. Pavord, et al. · Best Practice & Research Clinical Obstetrics & Gynaecology · 15
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025 · Hartmut Döhner, Andre Schuh, et al. · Blood · 14
PDF
P30 Single Cohort Results From Majestec-2: Teclistamab (tec) in Combination With Subcutaneous Daratumumab (dara) and Lenalidomide (len) in Patients With Multiple Myeloma (mm)
2023 · E. Searle, H. Quach, et al. · HemaSphere · 14
Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment
2017 · Emma J Searle, Brian A Telfer, et al. · EMBO Molecular Medicine · 14
PDF
Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy
2014 · E.J. Searle, T.M. Illidge, et al. · Clinical Oncology · 14
Inflammatory BCG adenitis associated with immune reconstitution following allogeneic haematopoietic stem cell transplant in infancy
2009 · E. Searle, H. Patel, et al. · Pediatric Blood & Cancer · 13
Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
2024 · Luciano J. Costa, Fredrik Schjesvold, et al. · Blood · 12
Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study
2024 · S. Collinson, S. Ingram-Walpole, et al. · Clinical Oncology · 10
S196: Elranatamab, a B-cell Maturation Antigen (bcma)-cd3 Bispecific Antibody, for Patients With Relapsed/refractory Multiple Myeloma: Extended Follow up and Biweekly Administration From Magnetismm-3
2023 · Mohamad Mohty, Michael H. Tomasson, et al. · HemaSphere · 7
P865: Teclistamab in Combination With Lenalidomide in Previously Treated Patients With Multiple Myeloma in the Phase 1b Multicohort Majestec-2 Study
2023 · Carlyn Tan, Emma Searle, et al. · HemaSphere · 7
Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).
2025 · Muhamed Baljevic, Peter M. Voorhees, et al. · Journal of Clinical Oncology · 6
Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
2022 · Luciano Nicosia, Nigel Brooks, et al. · Blood · 6
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
2025 · Jenny O'Nions, Andrew Wei, et al. · Blood · 5
Works count: 83
Citation count: 1,360
H-index: 14
I10-index: 19
Year
Topic
Type